JP2015502340A - ｉＮＫＴに対するヒト化抗体 - Google Patents

ｉＮＫＴに対するヒト化抗体 Download PDF

Info

Publication number
JP2015502340A
JP2015502340A JP2014539044A JP2014539044A JP2015502340A JP 2015502340 A JP2015502340 A JP 2015502340A JP 2014539044 A JP2014539044 A JP 2014539044A JP 2014539044 A JP2014539044 A JP 2014539044A JP 2015502340 A JP2015502340 A JP 2015502340A
Authority
JP
Japan
Prior art keywords
antibody
seq
human
subject
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014539044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502340A5 (enExample
Inventor
トルネ，アレムゼゲド
カー，フランシス，ジョセフ
ジョーンズ，ティモシー，デービッド
グレグソン，ジェイムズ，ピー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NKT Therapeutics Inc
Original Assignee
NKT Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NKT Therapeutics Inc filed Critical NKT Therapeutics Inc
Publication of JP2015502340A publication Critical patent/JP2015502340A/ja
Publication of JP2015502340A5 publication Critical patent/JP2015502340A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2014539044A 2011-10-27 2012-10-26 ｉＮＫＴに対するヒト化抗体 Pending JP2015502340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552337P 2011-10-27 2011-10-27
US61/552,337 2011-10-27
PCT/US2012/062124 WO2013063395A1 (en) 2011-10-27 2012-10-26 Humanized antibodies to inkt

Publications (2)

Publication Number Publication Date
JP2015502340A true JP2015502340A (ja) 2015-01-22
JP2015502340A5 JP2015502340A5 (enExample) 2015-12-17

Family

ID=48168549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539044A Pending JP2015502340A (ja) 2011-10-27 2012-10-26 ｉＮＫＴに対するヒト化抗体

Country Status (13)

Country Link
US (1) US9932402B2 (enExample)
EP (1) EP2755688A4 (enExample)
JP (1) JP2015502340A (enExample)
KR (1) KR20140093964A (enExample)
CN (1) CN103945867B (enExample)
AU (1) AU2012328588C1 (enExample)
BR (1) BR112014009962A2 (enExample)
CA (1) CA2853719A1 (enExample)
HK (2) HK1199405A1 (enExample)
IL (1) IL232017A0 (enExample)
RU (1) RU2014120694A (enExample)
SG (1) SG11201401319XA (enExample)
WO (1) WO2013063395A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522102A (ja) * 2020-04-20 2023-05-26 ジェンザイム・コーポレーション ヒト化抗補体Ｂｂ因子抗体およびその使用
JP2023522979A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉＮＫＴ細胞の活性化による老化細胞の排除

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159764A1 (en) * 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2015069697A2 (en) * 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
WO2015121393A1 (en) * 2014-02-14 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3190415B1 (en) * 2014-07-25 2019-05-01 Riken Memory invariant nkt cell marker
US20160022777A1 (en) * 2014-07-28 2016-01-28 Nkt Therapeutics Inc. Combination therapy with il-12
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
CN109152798B (zh) * 2015-12-02 2022-10-21 斯特库比股份有限公司 特异于糖基化的pd-1的抗体及其使用方法
EP3436475A1 (en) 2016-03-29 2019-02-06 STCube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
AU2017246794B2 (en) 2016-04-04 2024-07-04 Genzyme Corporation Anti-complement factor Bb antibodies and uses thereof
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
SI4339615T1 (sl) * 2016-09-16 2026-01-30 Shanghai Henlius Biotech, Inc. Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140487A2 (en) * 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
WO2010094981A2 (en) * 2009-02-20 2010-08-26 Fusion Antibodies Limited Antibody therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
WO1997016203A1 (en) 1995-11-01 1997-05-09 Genetics Institute, Inc. Methods for administration of il-12
US6162609A (en) 1997-12-31 2000-12-19 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic methods based upon Vα24JαQT cells
EP1297017B1 (en) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
CA2454048C (en) * 2001-07-17 2011-05-03 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
ATE549064T1 (de) 2002-06-14 2012-03-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft
US9809654B2 (en) * 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
ATE539757T1 (de) * 2004-11-02 2012-01-15 Univ Leland Stanford Junior Verfahren zur hemmung von nkt-zellen
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
WO2009015279A2 (en) * 2007-07-24 2009-01-29 National Jewish Medical And Research Center Agents and methods for inhibition of airway hyperresponsiveness
WO2009026412A1 (en) 2007-08-21 2009-02-26 Children's Medical Center Corporation Treatment of airway hyperreactivity
US8835613B2 (en) 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
EP2575824A4 (en) 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
EP2785683B1 (en) 2011-11-30 2020-02-05 Ludwig Institute for Cancer Research Ltd. Inkt cell modulators and methods of using the same
WO2015069697A2 (en) 2013-11-05 2015-05-14 Nkt Therapeutics Inc. Combination therapy
US20160022777A1 (en) 2014-07-28 2016-01-28 Nkt Therapeutics Inc. Combination therapy with il-12

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140487A2 (en) * 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
WO2010094981A2 (en) * 2009-02-20 2010-08-26 Fusion Antibodies Limited Antibody therapy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
EXLEY MA, ET AL.: "Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody speci", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 38, no. 6, JPN6017033699, 2008, pages 1756 - 1766, XP009175378, DOI: doi:10.1002/eji.200737389 *
FIELD JJ, ET AL.: "Targeting iNKT cells for the treatment of sickle cell disease.", CLINICAL IMMUNOLOGY, vol. 140, no. 2, JPN6016034312, 8 March 2011 (2011-03-08), pages 177 - 183, XP028242421, DOI: doi:10.1016/j.clim.2011.03.002 *
LISBONNE M, ET AL.: "Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation a", THE JOURNAL OF IMMUNOLOGY, vol. 171, no. 4, JPN6016034307, 2003, pages 1637 - 1641, XP008115225 *
NAKAMURA T, ET AL.: "CD4+ NKT cells, but not conventional CD4+ T cells, are required to generate efferent CD8+ T regulato", THE JOURNAL OF IMMUNOLOGY, vol. 171, no. 3, JPN6016034310, 2003, pages 1266 - 1271 *
PATTERSON S, ET AL.: "Human invariant NKT cells are required for effective in vitro alloresponses", THE JOURNAL OF IMMUNOLOGY, vol. 175, no. 8, JPN6016034309, 2005, pages 5087 - 5094 *
SAITO TI, ET AL.: "Invariant NKT cells are required for antitumor responses induced by host-versus-graft responses", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 4, JPN6017033702, 2010, pages 2099 - 2105 *
三宅 幸子: "NKT細胞と疾患", 臨床リウマチ, vol. 第２２巻，第２号, JPN6017033704, 2010, pages ｐ．１５４−１６０ *
伊庭善孝: "抗体作製の新技術", 癌の臨床, vol. 第４８巻，第２号, JPN6011000542, February 2002 (2002-02-01), pages ｐ．５５−６６ *
医学のあゆみ, vol. 第１９９巻，第９号, JPN6011000539, 1 December 2001 (2001-12-01), pages ｐ．６６３−６６７ *
日本臨牀, vol. 第６０巻，第３号, JPN6011000541, March 2002 (2002-03-01), pages ｐ．４３９−４４４ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522102A (ja) * 2020-04-20 2023-05-26 ジェンザイム・コーポレーション ヒト化抗補体Ｂｂ因子抗体およびその使用
JP7794758B2 (ja) 2020-04-20 2026-01-06 ジェンザイム・コーポレーション ヒト化抗補体Ｂｂ因子抗体およびその使用
JP2023522979A (ja) * 2020-04-23 2023-06-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉＮＫＴ細胞の活性化による老化細胞の排除

Also Published As

Publication number Publication date
CN103945867A (zh) 2014-07-23
IL232017A0 (en) 2014-05-28
CN103945867B (zh) 2018-01-02
AU2012328588A1 (en) 2014-04-24
EP2755688A4 (en) 2014-08-06
HK1199405A1 (en) 2015-07-03
WO2013063395A1 (en) 2013-05-02
BR112014009962A2 (pt) 2019-09-24
CA2853719A1 (en) 2013-05-02
SG11201401319XA (en) 2014-06-27
HK1199837A1 (en) 2015-07-24
RU2014120694A (ru) 2015-12-10
AU2012328588C1 (en) 2015-12-03
US9932402B2 (en) 2018-04-03
AU2012328588B2 (en) 2015-07-09
KR20140093964A (ko) 2014-07-29
US20130136735A1 (en) 2013-05-30
EP2755688A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
US9932402B2 (en) Humanized antibodies to iNKT
KR102311761B1 (ko) 항-Siglec-8 항체 및 그의 사용 방법
CN108135969B (zh) 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途
JP6846362B2 (ja) 線維性疾患を処置するための方法および組成物
AU2015222757B2 (en) Methods and compositions for treating Siglec-8 associated diseases
JP2017501744A5 (enExample)
KR20200016232A (ko) 알레르기성 안구 질환을 치료하기 위한 방법 및 조성물
US12448434B2 (en) Antibodies specifically recognizing Pseudomonas PcrV and uses thereof
CN116621987A (zh) 特异性识别假单胞菌pcrv或psl抗原的抗体组合以及双特异性抗体
CA3145139C (en) Antibodies specifically recognizing pseudomonas pcrv and uses thereof
AU2017235959A1 (en) Humanized antibodies to iNKT
HK40077426A (en) Methods and compositions for treating siglec-8 associated diseases
EA040553B1 (ru) Антитело к cd154, обладающее улучшенными характеристиками связывания, функциональности и безопасности, и его применение в иммунотерапии у человека

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180718